Abnormal expression of SRSF5 was reported in breast, renal, and lung cancers38, and studies identified SRSF5 involvement in the alternative splicing of HSD17B2 mRNA in prostate cancer and its regulation of tumor growth via alternative splicing of CCAR1 pre-mRNA in lung cancer39–41. Here, CCAR1 is linked to prostate carcinoma.